UNH Stock: Why Did The Healthcare Giant Stumble?

Core Insights - UnitedHealth Group (UNH) reported Q4 2025 earnings that slightly missed revenue expectations at $113.2 billion, compared to the anticipated $113.7 billion, while meeting EPS forecasts at $2.11. The company faced significant challenges with a nearly flat 0.09% increase in the Medicare Advantage rate for 2027, which was well below the expected 4-6% increase, and a surge in the medical care ratio to 88.9%, up 340 basis points year-over-year, leading to a 19% drop in stock price [2][4][12]. Financial Performance - Full-year 2025 revenue reached $447.6 billion, marking a 12% increase, but 2026 revenue guidance is projected to decline to over $439 billion, a decrease of 2% [11]. - Q4 2025 adjusted EPS was $2.11, down 65% from $5.98 in Q4 2024, with full-year 2025 adjusted EPS at $16.35 and 2026 adjusted EPS guidance exceeding $17.75, indicating an 8.6% growth [12]. - The operating margin for 2025 was 2.7%, with projections to improve to 5.5% in 2026 [12]. - Cash flow from operations was robust at $19.7 billion, which is 1.5 times net income, despite incurring a $1.6 billion restructuring charge and a $799 million revenue loss due to a cyberattack [12]. Medicare Advantage Challenges - The adjusted medical care ratio of 88.9% indicates that UNH is spending $0.89 of every premium dollar on medical claims, up from 85.5% in 2024, driven by a 7.5% increase in medical expenses for Medicare Advantage that outpaced pricing [4][5]. - The proposed 2027 rate increase is virtually zero, compounded by a new CMS policy that removes 1.53 percentage points from diagnoses not associated with actual medical visits, which will continue to squeeze margins [5][14]. Market Position and Valuation - UNH is experiencing its first annual revenue decline since 1989, with management planning to eliminate unprofitable Medicare Advantage members, anticipating a loss of about 1 million members in 2026 [7]. - At a current price of approximately $285, UNH trades at about 16 times the estimated EPS of $17.75 for 2026, which is below its historical trading range of 18-22 times forward earnings, suggesting a potential upside of 40% based on analyst consensus with a strong buy rating and an average price target of around $396 [9][12]. Regulatory and Structural Issues - There is ongoing regulatory uncertainty regarding the preliminary 0.09% rate, with final rates to be announced in April, alongside a DOJ investigation into Medicare billing practices and structural margin compression in Medicare Advantage [13][15]. - The 2027 rate proposal, if finalized, could fundamentally alter the economics of Medicare Advantage, posing significant short-term challenges for UNH despite its historical ability to adapt and achieve over 15% annual returns in the past decade [15].